Aberrant amyloid beta-protein precursor (ABPP) metabolism is probably a major early event in Alzheimer's disease (AD) pathogenesis leading to amyloid plaques. We and others have identified two major pathways for ABPP metabolism, viz. secretion and lysosomal degradation. Secretion involves cleavage from the membrane form to release a soluble, shorter N-terminal ABPP and a small membrane C-terminal reactive form. We do not yet know where normal cleavage is in relation to the beta-protein region, nor what processes are involved in regulating secretion v.s. putative lysosomal degradation. We have recently discovered that ABPP is regulated by fibroblast basic growth factor (FGF) and that FGF is elevated in AD brain and abnormally distributed in and around plaques suggesting a possible role in putative plaque-associated abnormalities in ABPP. We have recently reported preliminary evidence for reduced ABPP mRNA and ABPP release in cultured familial Alzheimer disease fibroblasts. Although the ABPP gene and a familial Alzheimer's disease (FAD) gene are both located on chromosome 21, it is not known whether the FAD gene modulates ABPP mRNA expression or ABPP metabolism. The proposed studies are designed to investigate these problems in genetically engineered human neuronal and fibroblast cell lines and in AD and control fibroblasts.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG009009-02
Application #
3120821
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Project Start
1990-05-02
Project End
1993-04-30
Budget Start
1991-05-01
Budget End
1992-04-30
Support Year
2
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Johnson, David K; Watts, Amber S; Chapin, Benjamin A et al. (2011) Neuropsychiatric profiles in dementia. Alzheimer Dis Assoc Disord 25:326-32
Hsiao, K; Chapman, P; Nilsen, S et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102
Tekirian, T L; Cole, G M; Russell, M J et al. (1996) Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains. Neurobiol Aging 17:249-57
Mak, K; Yang, F; Vinters, H V et al. (1994) Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res 667:138-42
Yang, F; Mak, K; Vinters, H V et al. (1994) Monoclonal antibody to the C-terminus of beta-amyloid. Neuroreport 5:2117-20
Frautschy, S A; Cole, G M; Baird, A (1992) Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol 140:1389-99
Cole, G M; Bell, L; Truong, Q B et al. (1992) An endosomal-lysosomal pathway for degradation of amyloid precursor protein. Ann N Y Acad Sci 674:103-17
Waite, J; Cole, G M; Frautschy, S A et al. (1992) Solvent effects on beta protein toxicity in vivo. Neurobiol Aging 13:595-9
Frautschy, S A; Baird, A; Cole, G M (1991) Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A 88:8362-6